Immutep’s Latest Breakthroughs Signal Hope for Cancer and Autoimmune Treatment
Immutep Limited, a biotech company from Sydney, is on a mission to turn cutting-edge science into real-world treatments for some of the most challenging diseases—cancer and autoimmune disorders. With their recent Q1 report for FY25, Immutep shared some remarkable milestones and their journey to change patient care. From regulatory green lights to innovative trials and new market recognition, the company’s story is one of dedication and growth.
Big News for Cancer Trials: Efti’s Rise
One of the biggest breakthroughs in the last few months for Immutep is the FDA’s approval for its upcoming TACTI-004 Phase III trial, where they’re testing their lead therapy, eftilagimod alfa (or “efti”), in combination with the cancer-fighting drug KEYTRUDA®.
This Phase III trial, which will enroll around 750 patients with first-line metastatic non-small cell lung cancer (NSCLC), is a huge step. By combining efti with a recognized treatment like KEYTRUDA, Immutep aims to address the cancer regardless of the patient’s PD-L1 levels, making the therapy potentially available to a broader group.
In short, Immutep is pushing to make their treatment an option for more lung cancer patients in a high-stakes global trial.
In another promising update, Immutep has been testing efti with KEYTRUDA on patients with head and neck cancers, where early results are exciting. Known as the TACTI-003 trial, this study has been focused on patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Results from patients with PD-L1 negative tumors show a 35.5% response rate, making this one of the most effective treatments so far for patients who otherwise have limited options.
Immutep even earned a spot at the prestigious ESMO Congress, where they presented data showing efti’s impact across different patient groups, proving that the therapy is both effective and well-tolerated.
Branching Out with Trials Beyond Cancer
While efti’s cancer trials dominate the headlines, Immutep isn’t stopping there. They’re now moving forward with the first human trial of IMP761, a new therapy aimed at autoimmune diseases. Unlike their cancer therapies, IMP761 is all about calming an overactive immune system.
Autoimmune diseases, where the body attacks its own cells, are difficult to treat because they involve delicate immune functions. Immutep’s approach with IMP761 is to “quiet” certain T cells that are causing this confusion in the body.
In simpler terms, this could mean relief for patients whose immune systems have gone haywire. The first trial has kicked off in the Netherlands, with safety data expected by the end of 2024.
Protecting Innovation and Gaining Ground
Immutep’s momentum also comes from securing seven new patents across territories including South Korea, Brazil, and Israel. These patents protect the core innovations behind efti and IMP761, giving Immutep a stronger foothold in the highly competitive world of biotechnology.
Each new patent is not just a legal win but a step toward ensuring the therapies can eventually reach patients in need.
And in another nod to their growth, Immutep was recently added to the S&P/ASX 300 index, an achievement that highlights the company’s growing market presence and visibility. Joining the ASX300 isn’t just a corporate milestone; it shows that Immutep has built investor confidence and expanded its impact in the Australian market and beyond.
As 2025 unfolds, Immutep looks forward to seeing the full results from its ongoing trials. The anticipated survival data from the TACTI-003 trial and safety outcomes from the IMP761 autoimmune study represent what could be life-changing treatments for patients worldwide.
Immutep’s Q1 FY25 report underscores a company making waves in biotechnology. With new FDA approvals, ambitious trials, and promising early results, they’re aiming to provide more patients with new ways to tackle tough diseases.
Advertisement:
Is Immutep a good investment?
Immutep Limited (ASX: IMM; NASDAQ: IMMP) is a biotechnology company specializing in LAG-3 immunotherapies for cancer and autoimmune diseases. Evaluating Immutep as a potential investment involves considering several key factors:
1. Pipeline and Progress
Clinical Trials: Immutep has shown promising results in its clinical trials for both cancer and autoimmune disease therapies. With their lead drug eftilagimod alpha (efti) in advanced trials for non-small cell lung cancer (NSCLC) and head and neck cancer, Immutep is advancing therapies that address significant markets and unmet needs. Positive results in these trials could boost the company’s value.
Strategic Partnerships: Collaborations, like with Merck for using KEYTRUDA® in combination therapies, provide both financial and operational support. Partnerships with major pharmaceutical companies validate Immutep’s research and expand their reach in the market.
In June 2024, Immutep announced a collaboration with Merck for a Phase III trial combining efti with KEYTRUDA® in treating metastatic non-small cell lung cancer. Concurrently, the company raised A$100 million through a capital raise, issuing new shares at a 15% discount to the last closing price. This funding is allocated for clinical trials, manufacturing, and working capital, ensuring financial stability for ongoing and planned projects. Source: The Australian
2. Financial Strength and Funding
Cash Position: Financially, Immutep is in a strong position with over A$172 million on hand, including cash reserves and short-term investments, which is expected to cover its funding needs through the end of CY2026. This financial cushion allows the company to continue its research and development activities without immediate funding concerns, an important stability factor for biotech investments.
This secure financial foundation is crucial for continuing trials and taking bold steps in research. With R&D tax rebates from both the Australian and French governments, Immutep has strategically managed funds to keep up its research momentum while lowering operational costs.
R&D Tax Incentives: Immutep benefits from tax incentives and rebates in both France and Australia, which reduce R&D costs and bolster cash flow. These support mechanisms may continue to enhance their financial stability.
Immutep Limited announced on 24 September 2024 it received a research and development tax incentive payment of €2,194,918 (~A$3.6 million) from the French government under its Crédit d’Impôt Recherche (CIR) scheme, which reimburses 30% of eligible R&D expenses. Immutep qualified for the incentive through its subsidiary, Immutep S.A.S., due to research conducted in France. The funds, related to 2023 EU R&D activities, will support the global clinical development of its immunotherapy treatments, eftilagimod alpha and IMP761. Additionally, Immutep receives similar R&D cash rebates from the Australian government for its work in Australia.
3. Market Recognition
ASX300 Inclusion: Being added to the S&P/ASX 300 index in September 2024 is a positive sign, as it brings greater visibility and potentially attracts institutional investors. This inclusion can increase share demand, leading to potentially higher valuations and better liquidity. Source: Yahoo Finance
Stock Performance: While subject to market volatility, Immutep’s inclusion in this index is indicative of its growing reputation and could positively influence its stock price over time.
4. Risks and Considerations
- Clinical and Regulatory Risk: As with any biotech firm, success is heavily reliant on clinical trial results and regulatory approvals. Failure or delays in trials could significantly impact Immutep’s stock price.
- Dependency on Partnerships: Immutep’s collaboration with larger companies like Merck is advantageous, but also brings dependency risks. Changes in these partnerships or a lack of continued interest from larger firms could impact Immutep’s development and market strategy.
- Market Competition: The immunotherapy market is highly competitive, with both established players and emerging biotech firms constantly innovating. Immutep’s ability to differentiate its products and secure a place in the market is critical for its long-term success.
Conclusion
Immutep’s financials indicate a company in the development phase, with substantial investments in R&D leading to operating losses. However, a strong cash position, strategic collaborations, and recent funding efforts provide a solid foundation for advancing its clinical programs. The inclusion in the S&P/ASX 300 index further underscores its progress and potential in the biotechnology sector.
Immutep holds promising potential for long-term growth due to its advanced research, financial backing, and strategic partnerships. However, its success hinges on the outcomes of its clinical trials and the broader competitive landscape. Investors with a high-risk tolerance and interest in the biotech sector might find Immutep a worthwhile investment, though monitoring its clinical progress and market conditions will be essential.
Immutep can be found on X (formerly Twitter), Facebook, LinkedIn and Youtube.
Disclaimer
The publisher of this website, 1EarthMedia, bought more shares of Immutep on Friday 1 November 2024 during a dip in share price.
Related stories
Over 55s Lifestyle Resort – Living Our Golden Years in Style
Advertisement:
